Krystal Biotech Reports Q2 2026 Financial Results

What Happened

• Krystal Biotech, Inc. (KRYS) filed a Form 8-K (Item 2.02) on August 3, 2026 announcing its financial results for the quarter ended June 30, 2026. The company attached a press release dated August 3, 2026 as Exhibit 99.1 to the filing. The 8-K was signed by Krish S. Krishnan, Chairman and Chief Executive Officer.

Key Details

• Filing date: August 3, 2026; quarter covered: ended June 30, 2026.
• Disclosure type: Item 2.02 — Results of Operations and Financial Condition; press release included as Exhibit 99.1.
• Legal note: the earnings information in the 8-K and Exhibit 99.1 is not deemed "filed" under Section 18 of the Exchange Act and is not automatically incorporated by reference into other SEC filings.
• Signature: Form 8-K signed by Krish S. Krishnan, Chairman & CEO.

Why It Matters

• This 8-K provides a timely company-issued summary of quarterly results; investors should review the attached press release (Exhibit 99.1) for revenue, earnings, updates or guidance details. The Section 18/legal disclaimer means the press release figures carry standard limits on SEC liability and won’t automatically become part of future registration statements—formal financial statements and disclosures will appear in periodic filings (e.g., the next 10-Q).